Three therapeutic monoclonal antibodies (AXL1717, MEDI-573, and BI836845) that neutralize IGF1/2 have the potential to counteract IGF2 repression of the immune reaction to cancer and its promotion of chemoresistance in cancer. This evidence concerns the gene IGF1 and cancer.